title: Meningitis C vaccine (North American vaccine).
abstract: North American Vaccine Inc (NAVI) has launched a conjugate polysaccharide vaccinefor the prevention of meningitis caused by group C meningococcal bacteria [433475]. The vaccine is based upon conjugate technology, incorporating the serogroup C polysaccharide (CPS) of all three major serogroups. Antibody-dependent, complement-mediated activity was demonstrated in mice and non-human primates, with no detectable adverse effects [277193]. Approval was filed for in the UK in January 2000 [353305]. In July 2000, Baxter received approval for NeisVac-C in the UK, and by September 2000 the vaccine was expected to be incorporated into the NHS's immunization campaign against meningitis C [381225]. NeisVac-C will initially appear labeled from NAVI; Baxter completed its acquisition of NAVI in June 2000 [375389]. Baxter estimates the worldwide global market for the vaccine at US $600 million per year [376204].
authors.affiliation: Chiron SpA, Siena, Italy. maria_lattanzi@chiron.it
authors.forename: Maria
authors.initials: M
authors.lastname: Lattanzi
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Del Giudice
mesh_terms: D002986:Clinical Trials as Topic / Q000379:methods / Q000706:statistics & numerical data; D006801:Humans; D008585:Meningitis, Meningococcal / Q000188:drug therapy*; D022401:Meningococcal Vaccines / Q000494:pharmacology / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000379:methods
chemical_list: D022401:Meningococcal Vaccines